Cargando…

Immunohistochemical Expression of Programmed Death Ligand 1(PDL1) in Endometrial Carcinoma and Its Relation to CD4 and CD8 Positive Immune Cells

OBJECTIVES: Endometrial cancer (EC) is the most common cancer of the female genital tract. Egypt showed a significant increase in incidence lately of which 25% were premenopausal. Advanced or recurrent disease are mostly unresectable and the traditional adjuvant therapy give modest results with deva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salama, Maha E, Khairy, Dina A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727331/ https://www.ncbi.nlm.nih.gov/pubmed/35901358 http://dx.doi.org/10.31557/APJCP.2022.23.7.2491

Ejemplares similares

Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
por: El Samman, Dina Mohamed, et al.
Publicado: (2021)

Immunohistochemical Expression of Programmed Death Ligand-1 (PDL-1) in Colorectal carcinoma and Its Correlation with Stromal Tumor Infiltrating Lymphocytes
por: ELfishawy, Mona, et al.
Publicado: (2020)

The Presence of PDL-1 on CD8+ Lymphocytes Is Linked to Survival in Neonatal Sepsis
por: Akhmaltdinova, Lyudmila L., et al.
Publicado: (2022)

PDL1‐positive exosomes suppress antitumor immunity by inducing tumor‐specific CD8(+) T cell exhaustion during metastasis
por: Chen, Ji, et al.
Publicado: (2021)

Reactive glia promote development of CD103(+)CD69(+) CD8(+) T‐cells through programmed cell death‐ligand 1 (PD‐L1)
por: Prasad, Sujata, et al.
Publicado: (2018)

Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study)
por: Ali, Safa Mohammed, et al.
Publicado: (2023)

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent
por: van Erp, Anke E.M., et al.
Publicado: (2017)

Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8(+) T Lymphocytes in Ovarian Carcinosarcoma
por: Zhu, Jun, et al.
Publicado: (2017)

Programmed death ligand 1 and tumor-infiltrating CD8(+) T lymphocytes are associated with the clinical features in meningioma
por: Zhang, Yaochuan, et al.
Publicado: (2022)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

Control of Tumors by Antigen-Specific CD8(+) T Cells through PDL1-Targeted Delivery of Antigenic Peptide
por: Feng, Po-Hao, et al.
Publicado: (2022)

Antithymocyte Globulin Inhibits CD8(+) T Cell Effector Functions via the Paracrine Induction of PDL-1 on Monocytes
por: Copic, Dragan, et al.
Publicado: (2023)

Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8(+) T-cell immune responses
por: Zhu, Ying, et al.
Publicado: (2018)

Blocking of PDL-1 Interaction Enhances Primary and Secondary CD8 T Cell Response to Herpes Simplex Virus-1 Infection
por: Channappanavar, Rudragouda, et al.
Publicado: (2012)

Suppressed Programmed Death 1 Expression on CD4(+) and CD8(+) T Cells in Psoriatic Patients
por: Bartosińska, Joanna, et al.
Publicado: (2017)

Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer
por: Ye, Qing, et al.
Publicado: (2021)

Sex-Associated Expression of Co-Stimulatory Molecules CD80, CD86, and Accessory Molecules, PDL-1, PDL-2 and MHC-II, in F480+ Macrophages during Murine Cysticercosis
por: Togno-Peirce, Cristián, et al.
Publicado: (2013)

Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer
por: Huang, Chih-Yang, et al.
Publicado: (2018)

Polo-Like Kinase 1(PLK1) Immunohistochemical Expression in Triple Negative Breast Carcinoma: A Probable Therapeutic Target
por: Salama, Maha E, et al.
Publicado: (2021)

Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer
por: Kim, Seok-Hyun, et al.
Publicado: (2019)

Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer
por: Baretti, Marina, et al.
Publicado: (2022)

Programmed Cell Death Protein 1–Positive CD8(+) T Cells in Multiple Sclerosis: Exhausted Fighters or Peacekeepers
por: Smolders, Joost, et al.
Publicado: (2022)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
por: Qi, Xiaoguang, et al.
Publicado: (2020)

Expression of programmed death-ligand 1, IRF1 and CD8 T lymphocyte infiltration in a primary subset of breast cancer patients in Sudan
por: Salih, Shahenaz S., et al.
Publicado: (2023)

Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology
por: Ha, Hyerim, et al.
Publicado: (2019)

PDL1Binder: Identifying programmed cell death ligand 1 binding peptides by incorporating next-generation phage display data and different peptide descriptors
por: He, Bifang, et al.
Publicado: (2022)

Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma
por: Chew, Mianxin, et al.
Publicado: (2020)

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types
por: Scognamiglio, Giosuè, et al.
Publicado: (2016)

CD69-oxLDL ligand engagement induces Programmed Cell Death 1 (PD-1) expression in human CD4 + T lymphocytes
por: Jiménez-Fernández, María, et al.
Publicado: (2022)

PDL1 Fusion Protein Protects Against Experimental Cerebral Malaria via Repressing Over-Reactive CD8(+) T Cell Responses
por: Wang, Jun, et al.
Publicado: (2019)

Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma
por: Gao, Yuan, et al.
Publicado: (2017)

Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4
por: Kumar, Gaurav, et al.
Publicado: (2021)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

The Expression of Programmed Death-1 on CD4(+) and CD8(+) T Lymphocytes in Patients with Type 2 Diabetes and Severe Sepsis
por: Jia, Yumei, et al.
Publicado: (2016)

Endotoxin Tolerant Dendritic Cells Suppress Inflammatory Responses in Splenocytes via Interleukin-1 Receptor Associated Kinase (IRAK)-M and Programmed Death-Ligand 1 (PDL-1)
por: Zhou, Yuping, et al.
Publicado: (2018)

CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism
por: Medler, Juliane, et al.
Publicado: (2022)

Immunohistochemical Expression and Prognostic Value of CD97 and Its Ligand CD55 in Primary Gallbladder Carcinoma
por: Wu, Jinsheng, et al.
Publicado: (2012)

CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression
por: Nagano, Mayuko, et al.
Publicado: (2021)

Immunohistochemical expression of T-cell subsets (CD4 and CD8) in oral lichen planus
por: Rassol, Hiba Jassim, et al.
Publicado: (2023)

Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas
por: Rajendran, Madhubala, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8l2n0t4euoflndhslc2p2m64jg